RA | RITUXAN® (rituximab) Proposed Mechanism of Action (MoA) in Rheumatoid Arthritis
A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar | Immunotherapy
Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text
Internet Scientific Publications
The Risk of Hyperglycaemia with the use of Rituximab in Rheumatoid Arthritis. Results from a Meta-analysis of Randomised Clinica
Rituximab (Rituxan) | American Journal of Neuroradiology
A review of the current use of rituximab in autoimmune diseases - ScienceDirect
Rituximab-related Severe Toxicity | SpringerLink
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
Rituximab - Wikipedia
Main mechanisms of action of rituximab and ways to increase its... | Download Scientific Diagram
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - The Lancet
Frontiers | Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience | Annals of the Rheumatic Diseases
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
Truxima (rituximab) for the Treatment of Cancer - Clinical Trials Arena
B-Cell Targeted Therapies: Clinical Trials Update
PV | RITUXAN® (rituximab) Proposed Mechanism of Action (MoA)
Empowering Targeted Therapy: Lessons from Rituximab | Science's STKE
Rituximab in dermatology | Actas Dermo-Sifiliográficas
Mechanism of action of rituximab. Rituximab is a monoclonal antibody... | Download Scientific Diagram
Novel therapeutic targets in rheumatoid arthritis: Trends in Pharmacological Sciences
JPM | Free Full-Text | Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis
Rituximab for the treatment of multiple sclerosis: a review | SpringerLink
